{"schema":"hottub-news/story/v1","story":"st_2qi5vesxh4yaaavgzvjq","title":"Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions","title_en":null,"outlets":5,"brief":null,"page":"https://hottub.news/stories/roche-presents-new-data-at-euretina-highlighting-vabysmos-real-world-2qi5vesxh4","count":5,"items":[{"id":"n_axlbl3fxsrkuv4to56lq","seq":1102818,"kind":"article","title":"Roche Highlights Real-World Vabysmo Performance Across Major Retinal Diseases At EURETINA","url":"https://www.rttnews.com/3695658/roche-highlights-real-world-vabysmo-performance-across-major-retinal-diseases-at-euretina.aspx","published":"2026-10-01T07:16:00Z","seen":"2026-10-01T09:50:09Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","business","health"],"story":"st_2qi5vesxh4yaaavgzvjq","category":"health","category_p":0.49000000953674316,"sentiment":"positive","tone":0.07999999821186066,"political":0.03999999910593033},{"id":"n_ld77jfwbj2wnlr54quxq","seq":1074060,"kind":"article","title":"Roche's Vabysmo Shows Real-World Effectiveness Across Retinal Diseases","url":"https://www.finanzen.ch/nachrichten/aktien/roches-vabysmo-shows-real-world-effectiveness-across-retinal-diseases-1036588323","published":"2026-10-01T07:12:45Z","seen":"2026-10-01T07:12:45Z","lang":"en","country":"CH","source":{"id":"finanzen.ch","name":"finanzen.ch","domain":"finanzen.ch"},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_2qi5vesxh4yaaavgzvjq","category":"health","category_p":0.7200000286102295,"sentiment":"positive","tone":0.36000001430511475,"political":0.019999999552965164},{"id":"n_frg5dwdwc64ixvpiomcq","seq":1072556,"kind":"article","title":"Roche presents new data at EURETINA, highlighting Vabysmo's real-world effectiveness and safety across major retinal conditions","url":"https://www.manilatimes.net/2026/10/01/tmt-newswire/globenewswire/roche-presents-new-data-at-euretina-highlighting-vabysmos-real-world-effectiveness-and-safety-across-major-retinal-conditions/2436783","published":"2026-10-01T06:16:00Z","seen":"2026-10-01T07:12:01Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","health","education","science"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_2qi5vesxh4yaaavgzvjq","category":"health","category_p":0.5400000214576721,"sentiment":"positive","tone":0.20000000298023224,"political":0.07000000029802322},{"id":"n_mi2dpgu6pb5rfsflmweq","seq":1101808,"kind":"article","title":"Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions","url":"https://www.timesargus.com/news/business/genentech-presents-new-data-at-euretina-highlighting-vabysmo-s-real-world-effectiveness-and-safety-across/article_0eb0b392-dff9-53d6-a36d-030cbc86475d.html","summary":"SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 1, 2026--","published":"2026-10-01T06:01:56Z","seen":"2026-10-01T09:49:09Z","lang":"en","country":"US","source":{"id":"kite-timesargus-com-f2ab3d","name":"timesargus.com","domain":"timesargus.com","outlet":{"wikidata":"Q4863287","name":"Barre Montpelier Times Argus","type":"newspaper","country":"US","designations":["newspaper"]}},"via":"kite-timesargus-com-f2ab3d","topics":["vermont"],"authors":["Business Wire"],"entities":[{"id":"Q899140","name":"Genentech","type":"org"},{"id":"Q140876515","name":"European Society of Retina Specialists","type":"event"}],"story":"st_2qi5vesxh4yaaavgzvjq","category":"health","category_p":0.36000001430511475,"category2":"science-technology","sentiment":"positive","tone":0.3799999952316284,"political":0.07999999821186066},{"id":"n_2qi5vesxh4yaaavgzvjq","seq":1065275,"kind":"press_release","title":"Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions","url":"https://www.globenewswire.com/news-release/2026/10/01/3372533/0/en/roche-presents-new-data-at-euretina-highlighting-vabysmo-s-real-world-effectiveness-and-safety-across-major-retinal-conditions.html","summary":"Basel, 1 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the VOYAGER study evaluating the effectiveness, durability and safety of Vabysmo® (faricimab) in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). 1-3 Across all study cohorts, results confirm the real-world effectiveness of Vabysmo in line with Phase III trial results, with vision gains and robust…","published":"2026-10-01T06:00:00Z","seen":"2026-10-01T06:15:39Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","swx:ro","otc markets:rhhby","swx:rog","ch0012032113","us7711951043","ch0012032048","9014"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q140876515","name":"European Society of Retina Specialists","type":"org"}],"mentions":2,"story":"st_2qi5vesxh4yaaavgzvjq","category":"health","category_p":0.550000011920929,"sentiment":"positive","tone":0.38999998569488525,"political":0.07000000029802322}]}